Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 6:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 130 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: H. Lundbeck A/S Clear all
Completed Phase 2 Interventional Results available

Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

NCT01491035
View directory record Official record
Conditions
Depressive Disorder, Anxiety Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Wichita, Kansas • Cincinnatti, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 1, 2026, 6:52 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

NCT06706622
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Amlenetug, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
40 Years to 75 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
23
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

NCT00672620
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
38
States / cities
Beverly Hills, California • Irvine, California • Santa Ana, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

NCT02079246
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Idalopirdine 60 mg
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
1,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 1, 2026, 6:52 PM EDT
Terminated Phase 3 Interventional Results available

Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder

NCT01944969
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 1, 2026, 6:52 PM EDT
Completed No phase listed Observational

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects

NCT00936676
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
Not listed
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women

NCT04405323
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06466, Itraconazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

NCT02400346
View directory record Official record
Conditions
Major Depression Disorder
Interventions
Adjunct brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
65 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Arcadia, California • Miami, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 1, 2026, 6:52 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Lu AF82422 in Participants With Multiple System Atrophy

NCT05104476
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Lu AF82422, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
40 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Fountain Valley, California • La Jolla, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 1 Interventional

Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)

NCT04597450
View directory record Official record
Conditions
PTSD
Interventions
Lu AG06466, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 1, 2026, 6:52 PM EDT
Terminated Phase 3 Interventional Results available

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

NCT02871297
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 18 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Tucson, Arizona • Wichita, Kansas • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease

NCT04149860
View directory record Official record
Conditions
Healthy, Alzheimer Disease
Interventions
Lu AF87908, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
6
States / cities
Glendale, California • Hollywood, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

NCT01670279
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
70 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Kissimmee, Florida • Miami, Florida • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 4 Interventional Results available

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

NCT03115827
View directory record Official record
Conditions
Parkinson Disease
Interventions
Droxidopa, Carbidopa
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 1 Interventional

Lu AF28996 in Participants With Parkinson's Disease (PD)

NCT04291859
View directory record Official record
Conditions
Parkinson Disease
Interventions
Lu AF28996
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
35 Years to 85 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Los Alamitos, California • Washington D.C., District of Columbia • Hallandale, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 1, 2026, 6:52 PM EDT
Terminated Phase 3 Interventional

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

NCT00396214
View directory record Official record
Conditions
Schizophrenia
Interventions
Bifeprunox, Quetiapine
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
69
States / cities
Anaheim, California • Cerritos, California • Costa Mesa, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 3 Interventional Results available

Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy

NCT01942785
View directory record Official record
Conditions
Major Depressive Disorder, Irritability
Interventions
Brexpiprazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
15
States / cities
Tucson, Arizona • Glendale, California • Oakland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines

NCT05074459
View directory record Official record
Conditions
Healthy Participants
Interventions
Eptinezumab Mammalian Cell Line, Eptinezumab Yeast Cell Line
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Daytona Beach, Florida • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Sep 1, 2026, 6:52 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

NCT03230864
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Lu AF35700, Risperidone, Olanzapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 2 Interventional

Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

NCT00139919
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Bifeprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

NCT03611569
View directory record Official record
Conditions
Healthy, Parkinson Disease
Interventions
Lu AF82422, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Glendale, California • Hollywood, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 1, 2026, 6:52 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS

NCT00467610
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Panhematin
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women

NCT03103646
View directory record Official record
Conditions
Cytochrome P450 Interaction
Interventions
Lu AF35700, Itraconazole (200 mg), Itraconazole (300 mg)
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 1, 2026, 6:52 PM EDT
Completed Phase 3 Interventional Results available

Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

NCT01795547
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole and aripiprazole once-monthly, Paliperidone and paliperidone palmitate
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 1, 2026, 6:52 PM EDT